What is the primary target for Atomoxetine's action in the brain?

Atomoxetine primarily targets norepinephrine transporters (NET) in the brain. It is a selective norepinephrine reuptake inhibitor, which means that it increases the availability of norepinephrine in the synaptic cleft by blocking the transporters responsible for its reabsorption back into the presynaptic neuron. This increased norepinephrine availability is particularly beneficial in the treatment of Attention Deficit Hyperactivity Disorder (ADHD), as norepinephrine plays a crucial role in regulating attention and impulsivity.

In contrast, while serotonergic neurons, dopaminergic neurons, and glutamatergic receptors are all important components of the central nervous system, they are not the primary targets of Atomoxetine. This specificity is what differentiates Atomoxetine from other medications that may affect multiple neurotransmitter systems, including those that target serotonin or dopamine. The focused action on norepinephrine transporters is key to its mechanism of action and efficacy in managing symptoms of ADHD.